Jubilant Life Sciences rose 3.07% to Rs 614.60 at 10:58 IST on BSE on bargain hunting after a recent slide.
Meanwhile, the BSE Sensex was up 55.88 points, or 0.21%, to 26,363.86.
On the BSE, so far 42,000 shares were traded in the counter, compared with average daily volumes of 1.51 lakh shares in the past one quarter. The stock had hit a high of Rs 618.50 and a low of Rs 605.95 so far during the day.
The stock hit a record high of Rs 726.40 on 1 December 2016. The stock hit a 52-week low of Rs 272.50 on 20 January 2016. The stock had underperformed the market over the past 30 days till 20 December 2016, falling 1.81% compared with the 2.11% rise in the Sensex. The scrip had, however, outperformed the market in past one quarter, falling 4.83% as against Sensex's 7.72% decline.
The mid-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.
Shares of Jubilant Life Sciences fell 7.28% in three trading sessions to settle at Rs 596.30 yesterday, 20 December 2016, from its close of Rs 643.15 on 15 December 2016.
The stock fell 3.92% to Rs 596.30 yesterday, 20 December 2016, after the company announced a price increase of up to 15% for its Beta Picoline, 3-Cyanopyridine and vitamin B3 (Niacin & Niacinamide) with immediate effect, for non-contract customers and wherever existing contracts permit. The announcement was made during trading hours yesterday, 20 December 2016.
On a consolidated basis, net profit of Jubilant Life Sciences rose 14.52% to Rs 144.77 crore on 5.16% decline in net sales to Rs 1359.70 crore in Q2 September 2016 over Q2 September 2015.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
